CANCELED DeviceConnect Event October 12: Modern Innovations in Diagnostics
Life Science Washington and Product Creation Studio present: DeviceConnect Series
The Puget Sound region has quietly become a leader in diagnostic innovation. Pandemic or not, our local institutions are converting exploratory R&D into meaningful diagnostic solutions. Our region is always up for the challenge! Join Life Science Washington, Product Creation Studio, and Cepheid for this DeviceConnect where we’ll talk with the researchers and device innovators who are thinking ahead while also addressing critically present needs.
You can learn more about the DeviceConnect series and our past events here!
Details
Date: Wednesday, October 12, 2022
Time: 4:00 - 5:30 PM
Location: Cepheid
1631 220th St SE
Bothell, WA 98021-8423 US
Cost: $25 for Life Science Washington members, $50 for non-members
Panelists
Ann Demaree
Senior Vice President, Marketing & Business Development at Cardiac Insight Inc.
Ann Demaree, MBA, BSN, RN is Senior Vice President of Business Development at Cardiac Insight, a leading Bellevue, WA USA-based digital health company revolutionizing cardiac arrhythmia diagnosis and research through its automated analysis software and prescription-grade wearable biosensors.
An executive team member at Cardiac Insight since 2017, Ms. Demaree has over 30 years of medical technology design, marketing, commercialization, consulting, and corporate M&A experience. She is licensed as a Registered Nurse in the States of Oregon and North Carolina and has served both as an invited faculty member and Industry Advisor to the Oregon Health & Science University Biomedical Innovation Program (BIP) and Clinical Translational Research Institute (OCTRI) since 2012.
Rhonda Rhyne
President and CEO at Prevencio, Inc
Rhonda Rhyne has deep industry experience in medical technology and machine learning, a subset of AI. She has more than 25 years of experience as an executive and board director developing and commercializing disruptive medical technologies. Ms. Rhyne led two start-up companies to rapid growth including CardioDynamics, a publicly-traded medical device company, which was sold to SonoSite FujiFilm.
Rhonda has been recognized as an industry leader including Ernst & Young Entrepreneur of the Year – Medical Products and Deloitte’s Fast 50 Award for 50 Fastest Growing Tech/Life Science Companies in Southern California for 9 years from 1999–2007.
Currently, Rhonda is President, CEO, and Board Director for Prevencio, Inc., a cardiac biomarker company developing novel Artificial Intelligence (AI)-driven, multi-protein in vitro diagnostic and prognostic tests for cardiovascular disease. Prevencio is also in partnership with Microsoft and Seattle Children’s Hospital (for custom diagnostics for Kawasaki Disease).
Rhonda also serves on the Board of Directors for Aminex Therapeutics and Life Science Washington. She earned an MBA from the UCLA Anderson School of Business Administration and a bachelor's degree in Pharmacy from Washington State University. She has also authored a leadership book, Keys to the Corner Office: Success Strategies for Women by Women.
Paul Yager, Ph.D.
Professor in the Dept. of Bioengineering at the University of Washington, CSO of UbiDX
Paul Yager, Ph.D., is a professor in the Department of Bioengineering at the University of Washington, with adjunct appointments in Chemistry, Global Health, and Oral Biology. A native of Manhattan, he received his A.B. in Biochemistry from Princeton in 1975, and a Ph.D. in Chemistry from the University of Oregon in 1980, specializing in vibrational spectroscopy of biomolecules.
After an NRC Fellowship at the Naval Research Laboratory (1980-1982), he joined the NRL staff as a Research Chemist. He moved to the Center (now Department) of Bioengineering at the University of Washington as Associate Professor in 1987, advancing to Professor in 1995; he served as Chair of the department from 2007 to 2013. Initially working on self-organizing lipid microstructure and optically-based biomedical sensors, since 1992 his lab has focused primarily on the development of microfluidics for the analysis of biological fluids for use in low-cost point-of-care biomedical diagnostics for the developed and developing worlds.
From 2005-2010 a team led by Yager was supported by the Bill & Melinda Gates Foundation to develop a low-cost rugged point-of-care system for pathogen identification. Since 2008, most lab activity has focused on developing two-dimensional porous networks (paper microfluidics) for ultra-low-cost instrument-free point-of-care pathogen identification for human diagnosis. Readout is often coupled with optical imaging for quantitative analysis and data transmission; this has been under the support of NIH, NSF, DARPA, DTRA, WRF, and the Emergent Ventures fund. He has authored 160 research publications in refereed journals, has 42 issued patents, and has co-founded 2 companies: Micronics and UbiDX.
Michael DeClue, Ph.D.
Director of Chemistry R&D at Cepheid
Michael DeClue, Ph.D. has multiple years of strategic and tactical business leadership experience and currently serves as the Director of Chemistry at Cepheid, enabling molecular diagnostic testing across the spectrum.
Michael brings to the panel extensive experience managing cross-functional teams, R&D, operations, synthetic & oligonucleotide chemistry, innovation, process optimization, process transfer, PCR primer & probe design, analytical chemistry, and project management. Successfully managed numerous project teams to support the launch of multiple commercial IVD products.
Scott Thielman (moderator)
CTO and Co-Founder at Product Creation Studio
Scott Thielman is CTO and co-founder of Product Creation Studio. With expertise in leading the development of consumer, medical and industrial products, Scott has participated in all aspects of development for clients including Philips, Johnson & Johnson, and Lilly. He holds a Ph.D. in mechanical engineering from the University of Washington and is a licensed professional engineer.